IVDR Performance Evaluation, Scientific Validity | Analytical and Clinical Performance
IVDR Performance Evaluation, Scientific Validity | Analytical and Clinical Performance - NKB Regovanta
Table of Contents
12 sections in this regulatory guidance
Many IVD teams have strong lab data but still get stuck in review. The reason is simple: reviewers want a clear story, not a pile of test results. A well-built IVDR performance evaluation and a clean analytical performance report give them that story.
This guide explains each part in plain English. You will learn what scientific validity means and what belongs in an analytical performance report. You will also see how clinical performance fits in, which deadlines apply, and how to avoid the mistakes that slow approvals.
What Is IVDR Performance Evaluation?
The In Vitro Diagnostic Regulation, Regulation (EU) 2017/746, requires every IVD maker to prove that the device works as claimed. That proof is called performance evaluation.
The regulation defines it as an assessment and analysis of data to establish or verify scientific validity, analytical performance and, where applicable, clinical performance. It runs across the whole device life cycle, so it never ends at launch.
Under the old directive, the focus sat mostly on analytical data. Now Article 56 and Annex XIII require three explicit pillars and a formal report. Your notified body reviews that report as part of your technical documentation.
Think of the process as a chain. Each link must connect to the next one. A break in the chain is what reviewers find first.
The Three Pillars: Scientific Validity, Analytical Performance and Clinical Performance
A simple way to remember the three pillars: scientific validity explains why the marker matters. Analytical performance shows how well you measure it. Clinical performance shows what the result means for patients.
Together, they feed the final performance evaluation report. The sections below explain each pillar.
Scientific Validity
Scientific validity is the association of an analyte with a clinical condition or physiological state. For example, haemoglobin links to anaemia.
You document this in a scientific validity report. Annex XIII lets you use one or a combination of sources. These include published literature, expert consensus from professional bodies, proof-of-concept studies, and data from devices that measure the same analyte.
Many analytes have strong literature behind them. However, you must still show a systematic search and a fair appraisal of the results.
Analytical Performance
Analytical performance shows how well your IVD detects or measures the analyte. Annex XIII, Part A, section 1.2.2 requires you to demonstrate it through analytical performance studies and record it in the analytical performance report.
Clinical Performance
Clinical performance shows that the test gives useful results in the target population. Typical measures include diagnostic sensitivity and specificity, predictive values and likelihood ratios. Teams gather this evidence from literature, existing data or a clinical performance study.
What Goes Into an Analytical Performance Report?
The analytical performance report is the document that proves your assay measures what you say it measures. It must link directly to your intended purpose and your claims.
A reviewer reads it with one question in mind: do these results support every claim on the label?
Core Parameters to Cover
Annex I lists the analytical characteristics to consider. The exact list depends on your device type. Common ones include:
- Analytical sensitivity and limit of detection (and limit of quantitation for quantitative tests)
- Analytical specificity, including interfering substances and cross-reactivity
- Trueness (closeness to a reference value)
- Precision, split into repeatability and reproducibility
- Measuring range and linearity
- Cut-off value verification
- Sample stability and specimen handling
If a parameter does not apply, say so and explain why. Silence invites questions.
How to Write It So Reviewers Trust It
Start with the study protocol, then show the raw outcome, then state the conclusion. Include acceptance criteria written before testing began. Link each result to the claim it supports.
Also name the reference methods, reagent lots and instruments used. Reviewers check whether you tested enough lots and enough samples to represent real use.
How the Performance Evaluation Plan and Report Fit Together
Good evidence starts with a plan. The performance evaluation plan (PEP) says what you will prove and how. The performance evaluation report (PER) says what you actually found.
Annex XIII requires the plan to cover the applicable general safety and performance requirements and the methods for showing scientific validity, analytical performance and clinical performance.
The PER then pulls everything into one document. According to Annex XIII, Part A, section 1.3.2, it must come from three reports: scientific validity, analytical performance and clinical performance. It also states the extent of the data you evaluated and your conclusion on conformity.
Where Guidance Helps
MDCG 2022-2 explains the general principles of clinical evidence for IVDs. Reviewers use it as a reference, so you should too. Write your PEP and PER so a reader can trace each claim back to a source in minutes.
The NKB Regovanta team describes its approach to this work on its IVDR performance evaluation service page.
How IVD Classification Changes Your Evidence Load
Your IVD classification shapes how deep the review goes. The IVDR uses Classes A, B, C and D under Annex VIII, Rules 1 to 7. Class D carries the highest risk.
Most IVDs now need a notified body. Only non-sterile Class A devices can self-declare. For Class D devices, extra checks apply, including involvement of EU reference laboratories.
Higher classes usually demand stronger clinical performance data. They also draw tougher questions on your analytical performance report. Check your class early, because it decides your budget and timeline.
NKB Regovanta lays out this step on its EU qualification and classification page.
IVDR Transition Deadlines You Cannot Ignore
Legacy devices got more time through Regulation (EU) 2024/1860. Under its transition rules, the deadlines run as follows:
| Class | Notified body application | Written agreement | End of transition |
|---|---|---|---|
| Class D | 26 May 2025 | 26 Sep 2025 | 31 Dec 2027 |
| Class C | 26 May 2026 | 26 Sep 2026 | 31 Dec 2028 |
| Class B and sterile Class A | 26 May 2027 | 26 Sep 2027 | 31 Dec 2029 |
These dates come from a BSI summary of the amending regulation. Manufacturers also needed an IVDR-compliant quality system by 26 May 2025.
Conditions apply, such as no significant design change. Therefore, confirm your eligibility before you rely on any date. NKB Regovanta offers help with MDD/IVDD to MDR/IVDR transition planning.
Common Mistakes in IVDR Performance Evaluation
Reviewers see the same errors again and again. Avoid these and you save months.
- Treating the report as a last step. Start the PEP before you finish design.
- Claims that outrun the data. Every label statement needs evidence.
- Disconnected documents. Risk files, the PEP, and the analytical performance report must agree.
- Thin literature work. A quick search does not prove scientific validity.
- Studies without pre-set criteria. Writing acceptance limits after testing looks biased.
- Ignoring the life cycle. Annex XIII, Part B requires ongoing post-market performance follow-up (PMPF).
- Wrong sample types. Test the specimens you claim, not convenient substitutes.
Each mistake weakens trust in your IVDR performance evaluation and analytical performance report. A mock review before submission catches most of them. NKB Regovanta supports this stage with notified body deficiency response.
How to Choose an IVDR Performance Evaluation Consultant
If you compare consultants, use a short checklist. A strong partner should answer yes to most of these.
- Do they know IVD science? Ask who writes the scientific validity and analytical sections.
- Have they supported your class? Class C and D need deeper evidence.
- Can they plan studies? A good consultant designs the analytical and clinical performance studies, not just the paperwork.
- Do they link documents? Look for a traceable chain from claim to evidence.
- Do they cover the life cycle? Ask about PMPF and post-market reports.
- Do they know your notified body? Familiarity speeds up questions and answers.
- Is the scope clear in writing? Avoid vague promises about speed.
Remember that the consultant prepares your file but does not replace the notified body’s judgment. A trustworthy firm says so openly. Also confirm who holds responsibility for study data, because manufacturers remain accountable.
What Practitioners Discuss Online
IVD professionals swap practical tips in public forums. Communities like r/medicaldevices and r/RegulatoryAffairs host threads on IVDR evidence, study design and notified body expectations.
Use these discussions to prepare sharper questions. However, treat each post as one person’s experience. Rules, reviewers and devices differ. Always check advice against the regulation, MDCG guidance and written feedback from your notified body.
Get Support with IVDR Performance Evaluation and Analytical Performance Reports
NKB Regovanta is an India-based regulatory consultancy with an office in Delaware, USA. Its EU MDR and IVDR services cover classification, performance evaluation, technical documentation and CE marking. Its In Vitro Diagnostics industry page explains how it works with diagnostics makers.
The team also helps with post-market clinical follow-up and PMPF, EUDAMED and economic operator duties, and ISO 13485 quality systems. You can read more articles in its Global Regulatory Insights hub or browse its case studies.
Ready to plan your evidence? Book a consultation and share your device, class and target date.
Frequently Asked Questions
What is IVDR performance evaluation?
It is the continuous process of proving that an IVD works as claimed. It covers scientific validity, analytical performance and, where applicable, clinical performance. Annex XIII of Regulation (EU) 2017/746 sets the rules.
What is an analytical performance report?
It is the document that records your analytical performance studies and results. It shows how well your assay detects or measures the analyte. It forms one input to the performance evaluation report.
What is scientific validity under IVDR?
Scientific validity is the link between an analyte and a clinical condition or physiological state. You prove it with literature, expert consensus, proof-of-concept data or similar sources. You record it in a scientific validity report.
What is the difference between analytical and clinical performance?
Analytical performance shows how well the test measures the analyte in the lab. Clinical performance shows how well the result matches a condition in real patients. Both feed the final report.
What goes into a performance evaluation report?
It includes the extent of the scientific validity, analytical performance and clinical performance data you reviewed. It also states your conclusion on conformity with the general safety and performance requirements.
Do all IVDs need a clinical performance study?
No. You must show clinical performance, but you may use literature or existing data when it is enough. A study becomes necessary when other evidence cannot support your claims.
How long does IVDR performance evaluation take?
It depends on your class, the existing data and the study design. Plan early, because studies and reviews take months. Ask your notified body for a current estimate.
When should I hire an IVDR performance evaluation consultant?
Hire one before you design your studies. Early input fixes evidence gaps while changes are cheap. Late rescue after a review rejection costs far more.
Notes for You (not part of the blog)
- Keyword form. Your keyword is a two-part string. I used it as a combined phrase (“IVDR performance evaluation and analytical performance report”) and as its separate parts throughout. The parts together appear well over 15 times, which exceeds 0.5%. I did not run a tool-based word count, so confirm length and density in your SEO plugin.
- Internal links. Your /insights page shows about 61 guides but no individual URLs. I linked verified service and industry pages instead. You can add deep links from the hub to these titles: IVDR Transition Planning: Check Eligibility Before Relying on the Deadline, Class D IVD Verification: Coordinate the Product Evidence and Batch Workflow, Clinical Equivalence Under EU MDR, GSPR Compliance: Turn the Checklist Into an Evidence Map, CDSCO IVD Registration Consultant | The Complete 2026 Guide, and IVD Registration Consultant in India.
- Page URLs. The IVDR performance evaluation page link comes from your EU services hub. My tool blocked a direct fetch of it, so please confirm that it loads.
- Reddit. My searches surfaced no usable thread URLs, and I would not invent them. I linked the two community pages. Please add one or two live threads manually.
- Verify before publishing. Check the deadline table against the official regulation text. Also confirm whether you want to rank for the Indian IVD angle, since your earlier post covered CDSCO classification.
NKB Regulatory Experts
Verified Regulatory ExpertM.Pharm, RAC (Global Regulatory Affairs Certified)
Senior Regulatory Affairs & Quality Assurance Specialists at NKB Regovanta Solutions Pvt. Ltd., guiding MedTech manufacturers worldwide across CDSCO, US FDA, EU MDR, and ISO 13485 compliance.
Facing medical device compliance bottlenecks or Notified Body review findings?
NKB Regovanta conducts thorough regulatory gap assessments, dossier remediation, and health authority liaison to secure market approvals with confidence.